Review



human lc3 duoset elisa  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 91
      Buy from Supplier

    Structured Review

    R&D Systems human lc3 duoset elisa
    Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and <t>LC3</t> (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.
    Human Lc3 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lc3+duoset+elisa/Human+LC3A+DuoSet+ELISA/pm36106817-75-12-16
    Average 91 stars, based on 1 article reviews
    human lc3 duoset elisa - by Bioz Stars, 2026-10
    91/100 stars

    Images

    1) Product Images from "Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS."

    Article Title: Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.

    Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

    doi: 10.1080/21678421.2022.2119868

    Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and LC3 (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.
    Figure Legend Snippet: Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and LC3 (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.

    Techniques Used: Biomarker Discovery, Control, Derivative Assay

    Figure 4. ALS-pathology related biomarker levels in PrimeC treated ALS patients over time. (A,B) Average ALS-pathology related serum NDE marker levels over time (pre in red, interim in light blue, and end of study in dark blue). (A) TDP-43 levels. (B) LC3 levels. (C,D) Average serum NFL (C) and pNFH (D) over time (pre in red, interim in light blue, and end of study in dark blue). P values tests whether the means at pre-treat are similar compared to the mean at end-of-treat, based on a mixed model for repeated measures.
    Figure Legend Snippet: Figure 4. ALS-pathology related biomarker levels in PrimeC treated ALS patients over time. (A,B) Average ALS-pathology related serum NDE marker levels over time (pre in red, interim in light blue, and end of study in dark blue). (A) TDP-43 levels. (B) LC3 levels. (C,D) Average serum NFL (C) and pNFH (D) over time (pre in red, interim in light blue, and end of study in dark blue). P values tests whether the means at pre-treat are similar compared to the mean at end-of-treat, based on a mixed model for repeated measures.

    Techniques Used: Biomarker Discovery, Marker

    Related Articles

    Enzyme-linked Immunosorbent Assay:

    Article Title: Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.
    Article Snippet: .. LC3 and TDP-43 were quantitatively measured in the NDE protein extracts using Human LC3 DuoSet ELISA (R&D Systems, Cat. No DY8558-05), and ELISA kit for TDP43 (MyBioSource, Cat No MBS2019049) per manufacturer’s instructions. ..



    Similar Products

    human lc3 duoset elisa  (R&D Systems)
    91
    R&D Systems human lc3 duoset elisa
    Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and <t>LC3</t> (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.
    Human Lc3 Duoset Elisa, supplied by R&D Systems, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lc3+duoset+elisa/Human+LC3A+DuoSet+ELISA/pm36106817-75-12-16
    Average 91 stars, based on 1 article reviews
    human lc3 duoset elisa - by Bioz Stars, 2026-10
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and LC3 (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.

    Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

    Article Title: Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.

    doi: 10.1080/21678421.2022.2119868

    Figure Lengend Snippet: Figure 3. ALS-pathology related NDE biomarker levels in ALS vs. control samples. Wilcox test comparing neural-derived blood exosomal biomarkers: TDP-43 (A) and LC3 (B) between patients with ALS and healthy volunteers (N ¼ 35 for ALS and 25 for control per group) as obtained in a baseline study.

    Article Snippet: LC3 and TDP-43 were quantitatively measured in the NDE protein extracts using Human LC3 DuoSet ELISA (R&D Systems, Cat. No DY8558-05), and ELISA kit for TDP43 (MyBioSource, Cat No MBS2019049) per manufacturer’s instructions.

    Techniques: Biomarker Discovery, Control, Derivative Assay

    Figure 4. ALS-pathology related biomarker levels in PrimeC treated ALS patients over time. (A,B) Average ALS-pathology related serum NDE marker levels over time (pre in red, interim in light blue, and end of study in dark blue). (A) TDP-43 levels. (B) LC3 levels. (C,D) Average serum NFL (C) and pNFH (D) over time (pre in red, interim in light blue, and end of study in dark blue). P values tests whether the means at pre-treat are similar compared to the mean at end-of-treat, based on a mixed model for repeated measures.

    Journal: Amyotrophic lateral sclerosis & frontotemporal degeneration

    Article Title: Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS.

    doi: 10.1080/21678421.2022.2119868

    Figure Lengend Snippet: Figure 4. ALS-pathology related biomarker levels in PrimeC treated ALS patients over time. (A,B) Average ALS-pathology related serum NDE marker levels over time (pre in red, interim in light blue, and end of study in dark blue). (A) TDP-43 levels. (B) LC3 levels. (C,D) Average serum NFL (C) and pNFH (D) over time (pre in red, interim in light blue, and end of study in dark blue). P values tests whether the means at pre-treat are similar compared to the mean at end-of-treat, based on a mixed model for repeated measures.

    Article Snippet: LC3 and TDP-43 were quantitatively measured in the NDE protein extracts using Human LC3 DuoSet ELISA (R&D Systems, Cat. No DY8558-05), and ELISA kit for TDP43 (MyBioSource, Cat No MBS2019049) per manufacturer’s instructions.

    Techniques: Biomarker Discovery, Marker